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httpcense.Abstract Study objective: This study analyses for the ﬁrst time endothelin-1 (ET-1) level, and gene
polymorphisms for endothelin-1 (EDN1 gene) in patients with pulmonary arterial hypertension
(PAH) in Egypt.
Design: Cross-sectional study.
Setting: Large, tertiary care, Alexandria university teaching hospital, Chest Department.
Subjects: Thirty subjects with PAH with 30 control subjects.
Methods: Subjects were divided into two groups of matched age and sex were allocated. The ﬁrst
group consisted of thirty subjects, P18 years one group with no apparent evidence of disease free
from pulmonary hypertension after full medical history, examination, and selected investigations
(control group). The second group consisted of thirty subjects, P18 years, suffering from pulmon-
ary hypertension. All subjects who had a documented pulmonary hypertension with routine Echo-
doppler study were screened for endothelin-1(ET-1) and Gene polymorphism.
Measurements and results: This study analyzed the frequency and the potential role of endothe-
lin-1 and gene polymorphisms, the +134 del/insA, located in the gene encoding for endothelin-1
(EDN1) in PAH. Thirty patients with pulmonary hypertension (12 [40%] men) were included in
the study (Table 1). The mean age of the patients was 53.5 ± 12.8 years range from 34 to 72 years.
The two groups of patients and control subjects were matched as regard the age and gender. The
endothelin-1 mean was 1.8 ± 1.3 fmol/ml with range from 0.3 to 3.8 fmol/ml in the patients group.
The endothelin-1 mean was 0.7 ± 0.05 fmol/ml with range from 0.6 to 0.75 fmol/ml in the patientsxandria Faculty of Medicine,
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. Ibrahim).
e Egyptian Society of Chest
g by Elsevier
of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
://dx.doi.org/10.1016/j.ejcdt.2012.09.014
496 E. Ibrahim et al.group. There was a signiﬁcantly higher level of endothelin-1 in the group of pulmonary hyperten-
sion (p< 0.001). For the groups of polymorphisms studied, there was three genotypes (GT, TT,
and GG), no substantial differences in genotype and allele distributions for +134 del/insA located
in EDN1 gene, between PAH patients and control population, were observed (DF = 1;
C.I. = 95.0; and p= 0.226). The genotype GG show the highest level of endothelin while the
TT type show the lowest value of endothelin-1. Also, we found a signiﬁcant relation between the
higher endothelin-1 level and the lower oxygen saturation (p= 0.049), and the higher meanPAP
(p= 0.004).
Conclusions: In conclusion, our ﬁndings suggest a potential link between endothelin-1 level and
speciﬁc genotypes in the EDN1 gene and susceptibility for PAH with a worse haemodynamic pro-
ﬁle. Further investigations are warranted to understand the molecular basis and to conﬁrm the
potential clinical importance of these ﬁndings on larger cohorts of patients with PAH. This will
impact on the management of PAH of Egyptian patients in the near future.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
The term pulmonary arterial hypertension (PAH) describes a
rare group of diseases characterized by raised pulmonary vas-
cular resistance, resulting from vascular remodeling in the pre-
capillary resistance arterioles. Left untreated, patients die from
right heart failure, with a mortality approaching most serious
cancers. Endothelin-1(ET-1) is not only a potent vasoconstric-
tor, but causes proliferation of many of the vascular cells in-
volved in vascular remodeling. Although produced mainly by
the vascular endothelium, other cells such as smooth muscle,
ﬁbroblasts and macrophages are known sources of ET-1 when
these cells are challenged by relevant stimuli. Plasma ET-1 lev-
els are raised in patients with PAH and correlate with
important clinical outcomes. Furthermore, ET-1 receptor
antagonism has been demonstrated to improve both morbidity
and mortality in conditions associated with PAH. Many arti-
cles in the literature supporting the role for ET-1 in the path-
ogenesis of PAH [1].
Pulmonary arterial hypertension (PAH) is a serious dis-
ease. Its prognostic is based on the functional status quanti-
ﬁed by the NYHA class and the 6-min walking test, and the
hemodynamic data. The algorithms of treatment are solely
based on the hemodynamic data and the functional status
[2].
ET-1 has an important role as vasoconstrictor and mitogen
factor and its plasma levels have been found increased in PAH
[3]. This molecule’s effects are mediated by two receptors, ETA
and ETB, found, respectively, on vascular smooth muscle and
endothelial cells. They are G-protein-coupled receptors, and
ET-1 vasoconstrictor effects depend on smooth muscle cell
intracellular pH alkalinisation and Ca2+ increase [4]. The
two receptors have different roles: in short terms, ETA is impli-
cated only in vasoconstriction by increasing intracellular cal-
cium, while ETB stimulation causes ﬁrst a vasodilatation,
followed by vasoconstriction and has also a role in ET-1 clear-
ance. Polymorphic changes in EDN1 (encoding for endothelin-
1, ET-1) and EDNRA (encoding for endothelin receptor type
A; ET-A) genes have been suggested to play a role in human
heart diseases, such as hypertension and dilatated cardiomyop-
athy. To date, polymorphic changes in these genes have not
been studied in patients with pulmonary artery hypertension
(PAH) [5–7].Patients and methods
Subjects
All subjects or their ﬁrst degree relatives did sign an informed
consent for the research. Thirty patients with diagnosis of pul-
monary hypertension were included in the study. Thirty con-
trol subjects were included in the study. All subjects were
subjected to the following: full history taking including past
history of medical diseases and drug history. Also history of
diabetes mellitus (conﬁrmed by fasting blood glucose measure-
ment), heart failure (conﬁrmed by echocardiography), ischemic
heart diseases and arrhythmias, obstructive lung disease, inter-
stitial lung diseases, renal, and hepatic disease were included.
Subjects were divided into two groups of matched age and
sex were allocated. The ﬁrst group consisted of thirty subjects,
P18 years one group with no apparent evidence of disease free
from pulmonary hypertension after full medical history, exam-
ination, and selected investigations (control group). The second
group consisted of thirty subjects, P18 years, suffering from
pulmonary hypertension. All subjects who had a documented
pulmonary hypertension with routine Echodoppler study were
screened for endothelin-1(ET-1) and gene polymorphism.
Deﬁnition
We deﬁned pulmonary hypertension (PAH) by measuring
mean Pulmonary Artery Pressure (mPAP) and pulmonary
hypertension (PAH) was deﬁned as an increase in the mean
pulmonary arterial pressure (mPAP) to >25 mmHg at rest [8].
Measurement of serum big endothelin-1
Measurement of serum big endothelin-1 (Big ET). Blood samples
were obtained early in the morning. The big endothelin-1 levels
in serum was measured by commercially available enzyme linked
immunosorbent assay (ELISA) kits (Biomedica Group) [9].
Genotyping
Genomic DNA was extracted from peripheral whole blood
samples collected in tubes with EDTA. The primers that were
used in PCR ampliﬁcation reaction were designed with Pri-
mer3 program, v.0.4.0, using genomic sequences from gene
database on National Center for Biotechnology Information
website, http://www.ncbi.nlm.nih.gov, (EDN1 Gene ID:




















Mean ± S.D. 55.57 ± 14.29
EF%
Range 38.0–76.0
Mean ± S.D. 56.03 ± 9.81
FS%
Range 18.0–44.0
Mean ± S.D. 30.0 ± 5.60
Table 3 Comparison between the two studied groups regard-







* Signiﬁcant p< 0.05.
The role of the biomarker and the genetic polymorphism 4971955). We produced one amplicon for each polymorphism
studied, by real time polymerase chain reaction (PCR): each
reaction has a total volume of 25 ll, and was performed using
12 ng of genomic DNA, 0.5 mM dNTPs mix, 10 mM Tris–HCl
pH 8.3, 50 mM KCl, 2 mM MgCl2, 2.5 pmol of each primer,
0.75 U of SYBR Green qPCR Master Mix (Stratagene
Max 3000). Primer sequences and annealing temperature for
+134 del/insA (EDN1) were forward 50-CTCCTGCAGTCC-
CAGCTC-30, reverse 50-CATGAGCAAATAATCCATTC-
TG-30 (55 C) corresponding to a 245-bp length fragment.
Genotype/phenotype analysis and statistical methods
Descriptive statistics including frequency, distribution, mean,
and standard deviation were used to describe different charac-
teristics. Hardy–Weinberg equilibrium was calculated by chi-
square test with one degree of freedom. Genotype frequencies
between groups were compared by the Mann–Whitney U test
or the chi square-testing, as appropriate (2 groups), or the AN-
OVA test (3 groups). Univariate correlation was found by
Pearson’s analysis. A stepwise forward logistic multivariate
model was used to test the effect of signiﬁcant variables ob-
tained by univariate models. Variables’ rejection was employed
at the 0.05 signiﬁcance level. Data were analyzed using Statis-
tical Package for the Social Sciences (SPSS) Version 18.0 for
Windows (SPSS Inc, Chicago, IL, USA).
Results
Thirty patients with pulmonary hypertension 12 men (40%)
and 18 female (60%) were included in the study (Table 1).
The mean age of the patients was 53.5 ± 12.8 years range from
34 to 72 years. The two groups of patients and control subjects
were matched as regard the age and gender (Table 1). There
were 7 (23.3%) smokers. Table 2 demonstrates the clinical data
of the studied subjects which shows that COPD was the high-
est cause for secondary pulmonary hypertension 10 (33.3%).
Most of our patients had secondary pulmonary hypertension
(80%). The mean oxygen saturation was 88.76 ± 3.68%,
mean pulmonary artery pressure was 55.57 ± 14.29 mmHg,
Ejection Fraction (EF) was 56.03 ± 9.81%, and Fraction
Shortening was 30.0 ± 5.60%.
The endothelin-1 mean was 1.8 ± 1.3 fmol/ml with range
from 0.3 to 3.8 fmol/ml in the patients group. The endothe-
lin-1 mean was 0.7 ± 0.05 fmol/ml with range from 0.6 to
0.75 fmol/ml in the patients group (Table 3). There was a
signiﬁcantly higher level of endothelin-1 in the group of
pulmonary hypertension (p< 0.001). For the groups of poly-
morphisms studied, there was three genotypes (GT, TT, and
GG), no substantial differences in genotype and allele distribu-Table 1 Pulmonary hypertension and control subjects demo-
graphic data.
Characteristic PHT Control p value
Age (Years) 53.56 ± 12.8 51.6 ± 13.9 0.61
Gender
M 12 (40%) 9 (30%) 0.33
F 18 (60%) 21 (70%)
Smoking 7 (23.3%) 6 (20%) 0.68
M, male; F, female; PHT, pulmonary hypertension.tions for +134 del/insA located in EDN1 gene, between PAH
patients and control population, were observed (DF = 1;
C.I. = 95.0; and p= 0.226) (Table 4). The genotype GG
shows the highest level of endothelin-1 while the TT type
shows the lowest value of endothelin-1 and it was statistically
signiﬁcant (p= 0.0001) (Table 5).
We studied the correlation between the different studied
parameters (Table 6) and we found a signiﬁcant relation be-
tween the higher endothelin-1 level and the lower oxygen sat-
uration (p= 0.049), and the higher meanPAP (p= 0.004).
Also, there was a signiﬁcant correlation between lower oxygen
saturation and the higher meanPAP (p= 0.011). Additionally,
there was a logic signiﬁcant correlation between the EF% and
FS% (p= 0.0001).
The ROC curve was done to determine the best sensitivity,
speciﬁcity of endothelin-1 serum level as a diagnostic tool in
PH. The sensitivity of endothelin-1 was 80% and speciﬁcity
was 100% in detecting PAH at a cut off value of 0.525 fmol/ml.
Table 4 Hardy–Weinberg analysis of the genotype in the two
studied groups:comparison of genotypes and allele frequencies
between controls and patients.
Gene polymorphism Group Total
Patients group Control group
GT
No. 9 15 24
% 30.0% 50.0% 40.0%
TT
No. 3 4 7
% 10.0% 13.3% 11.7%
GG
No. 18 11 29
% 60.0% 36.7% 48.3%
Total
No. 30 30 60





DF= degree of freedom, CI = conﬁdence interval. p= signiﬁ-
cance p< 0.05.
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Test result variable(s): Enothelin
Positive if greater than or equal to(a) Sensitivity 1 – Speciﬁcity
0.525 0.800 1.000a = The smallest cutoff value is the minimum observed test value
minus 1, and the largest cutoff value is the maximum observed test
value plus 1.Discussion
This study analyzed for the ﬁrst times both serum endothelin-1
level (ET-1), and gene polymorphisms for endothelin-1 (EDN1
gene) among a sample of Egyptian patients with pulmonary
arterial hypertension (PAH). The main ﬁnding of the studywas the association between the endothelin-1 level and the
presence of the pulmonary hypertension, as well as, the associ-
ation of GG genotype with higher endothelin-1 level in PHT
patients. There was a signiﬁcantly higher level of endothelin-
1 in the group of pulmonary hypertension (p< 0.001). For
the groups of polymorphisms studied, there was three geno-
types (GT, TT, and GG), no substantial differences in geno-
type and allele distributions for +134 del/insA located in
EDN1 gene, between PAH patients and control population
with a degree of freedom = 1; C.I. = 95.0; and p= 0.226.
The genotype GG showed the highest level of endothelin-1
while the TT type showed the lowest value of endothelin-1.
Also there was a signiﬁcant relation between the higher endo-
thelin-1 level and the lower oxygen saturation (p= 0.049), and
the higher mean PAP (p= 0.004). As regards the sensitivity,
speciﬁcity of endothelin-1; it was found that the sensitivity
was 80% and speciﬁcity was 100% in detecting PAH at a
cut off value of 0.525 fmol/ml.
The pathogenesis of PAH is dominated by a signiﬁcant
increase of pulmonary vascular resistance, due to cellular
and biochemical modiﬁcations that lead to endothelial dys-
function, vasoconstriction, arterial wall thickening and
thrombosis [10,11]. ET-1 has an important role as a vaso-
constrictor and mitogen factor, and its plasma levels have
been found increased in PAH [12]. ET-1 effects are mediated
by two receptors, ETA and ETB, found, respectively, on vas-
cular smooth muscle and endothelial cells [4]. In patients
with moderate/severe PAH, pre-pro ET-1 mRNA levels in
endothelial tissue of small arteries are signiﬁcantly increased
[13]. We found a signiﬁcant relation between ET-1 level and
severity of PAH. Previous studies on rats with PAH evi-
dence endothelin receptor down regulation and a subsequent
increase of vascular production of ET-1 and its mRNA, as
well as a reduction of signal transduction [14]. Clinical inves-
tigations report an association between plasma ET-1 levels
and PAH severity and outcome. All these data may suggest
a key role for ET-1 and its receptors in PAH pathophysiol-
ogy [15].
ET-1 and its receptors encoding genes polymorphisms
have been previously studied [10]. That study looked at
two polymorphisms: the +134 ins/delA situated in 50UTR
of EDN1 gene and the His323His located in the sixth exon
of EDNRA gene [16]. The +134 ins/delA polymorphism
correlates to endothelin-1 levels in a study ex vivo per-
formed by Popowski et al. [17]. They found that the adenine
insertion is related to an increasing level of endothelin
expression (measured as pre-pro-ET-1 mRNA) with an evi-
dent increase in I/I homozygous carriers (3.9-fold respect
to the wild-type D/D carriers). However, our study fails to
demonstrate a role of this polymorphism in patients with
PAH.
However, we found that genotype GG shows the highest
level of endothelin-1 while the TT type shows the lowest va-
lue of endothelin-1. That could be due to racial factor of
our population which is for the ﬁrst time studied for PAH
and possible role of gene polymorphism and also for the
small sample size and that most of (80%) our patients have
a secondary PAH which is different from other study where
TT genotype was the most common type for PAH as their
patients had primary PAH [18]. This also, explain the lower
number of TT genotype as we have only 20% of our pa-
tients with primary PAH.
Table 5 Relation between level of endothelin-1 and the genotype in the two studied groups.
Group Gene polymorphism Endothelin-1 p
Min. Max Mean S.D.
Patients group GT .30 .85 .6333 .26101 19.415 .0001*
TT .40 .60 .4833 .10408
GG 1.10 3.80 2.6444 1.21980
Control group GT .60 .75 .7033 .05499 1.02 0.365
TT .70 .75 .7250 .02887
GG .60 .75 .7000 .05916
* Signiﬁcant p< 0.05.
Table 6 Correlation between different studied parameters.
Enothelin Age O2 Mean PAP EF%
Age r .048
p .802
O2 r .362* .058
p .049 .759
Mean PAP r .505** .044 .456*
p .004 .816 .011
EF% r .065 .109 .152 .087
p .734 .567 .421 .646
FS% r .054 .029 .122 .013 .847**
p .777 .880 .521 .948 .0001
* Correlation is signiﬁcant at the 0.05 level (2-tailed).
** Correlation is signiﬁcant at the 0.01 level (2-tailed).
The role of the biomarker and the genetic polymorphism 499Conclusion
Our ﬁndings suggest a potential link between endothelin-1 level
and speciﬁc genotypes in the EDN1 gene and susceptibility for
PAH with a worse haemodynamic proﬁle. Further investiga-
tions are warranted to understand the molecular basis and to
conﬁrm the potential clinical importance of these ﬁndings on
larger cohorts of patients with PAH. This will impact on the
management of PAH of Egyptian patients in the near future.
Understanding the role of EDN-1 in PAH has therapeutic sig-
niﬁcance since EDN1 receptor antagonists are currently few of
the best possible options available in treatment of PAH. Studies
have shown that addition of sildenaﬁl to bosentan treatment
could elicit additional hemodynamic beneﬁts in PAH patients.
Study limitations
Although our study and previous experimental and clinical
studies [15,13] suggest a potential role of endothelin-1 level
and EDN1 gene polymorphisms in the pathophysiology of
PAH, the main limitation of the present study is the lack of
demonstration of an in vitro functional role for this genotype.
Pathogenesis of PAH is incompletely characterized, but it is
likely to be multifactorial, involving the interaction between
the genetic milieu and the environment of the individual.
Endothelin-1 and endothelin receptor gene polymorphisms
are probably disease modiﬁers, and their interactions with
other genes and environmental features should be analyzed
in future investigations. Moreover, the relatively small limitedcohort of patients and the inclusion of various PAH pheno-
types may represent another potential bias.
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